Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

The fixed-dose co-formulation of Viread/Emtriva has an estimated user fee deadline of Sept. 12; a decision on GSK’s combo is expected in August. Results from a study of Viread, Emtriva and Sustiva are due by year end, Gilead said.
Advertisement

Related Content

Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy
GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead
GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead

Topics

Advertisement
UsernamePublicRestriction

Register

PS059438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel